Adam Feuerstein ✡️ ✓
@adamfeuerstein · Boston, MA · joined 05 Jan 2010
Biotech reporter @statnews. Dog ❤️er. Polk Award winner. #COYS. Said one analyst: The likes of Adam Feuerstein attack viciously. On Signal: stataf.54
131 286Followers
803Following
84 690Posts total
2MViews on collected posts
Neueste Beiträge
Wir suchen neue Beiträge…
@adamfeuerstein A now prescient quote https://t.co/SNwjLEqI2m
961 views · 8 likes
· 0 reposts · 0 replies
Open on X →
@adamfeuerstein Could this be another miss driven by insufficient knockdown? At this point, for straightforward hepatic protein suppression, it’s getting harder to justify ASOs when siRNA can deliver deeper and more durable knockdown.
1.2K views · 5 likes
· 0 reposts · 0 replies
Open on X →
This late Friday $NVS Lp(a) news is not good. Damn...
Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events...
47.2K views · 119 likes
· 16 reposts · 11 replies
Open on X →
@adamfeuerstein Five years ago $RARE was $100 per share; tomorrow will open below $15. That should be it for Emil Kakkis.
843 views · 3 likes
· 0 reposts · 0 replies
Open on X →
Ultragenyx $RARE drug to treat Angelman syndrome, a rare disease, fails late-stage trial https://t.co/wPySlAvJhn via @Jasonmmast
20.8K views · 29 likes
· 2 reposts · 2 replies
Open on X →
No spin in the $RARE Angelman study press release. Disappointing results for everyone, but no excuses either.
10.2K views · 54 likes
· 2 reposts · 2 replies
Open on X →
@adamfeuerstein condolances @BenFranksAltEgo
967 views · 2 likes
· 0 reposts · 1 replies
Open on X →
Ultragenyx $RARE announces Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve primary endpoint
32.1K views · 58 likes
· 2 reposts · 7 replies
Open on X →
Follow-up on $QURE confirmatory study in Huntington's, per Sami Corwin at William Blair:
"Alignment reached on key elements of confirmatory trial. In a follow-up with management, it indicated that the company reached alignment on the key elements of the confirmatory trial. The
22.9K views · 78 likes
· 9 reposts · 4 replies
Open on X →
@adamfeuerstein It really is very, very exciting. The ability to use infinitely variable mRNA in specialty vaccines is a godsend.
2.6K views · 57 likes
· 3 reposts · 1 replies
Open on X →
We just crossed a line in medicine that humanity has been walking toward for a hundred years.
For the first time, doctors can take a biopsy of your specific tumor, read its unique DNA mutations — the exact fingerprint no other cancer on earth shares — and build a custom mRNA
823.2K views · 14.3K likes
· 3.1K reposts · 315 replies
Open on X →
I have to say, when Merck called me last night with the mRNA cancer vaccine news (embargoed, of course), I literally yelped in reaction.
Consider this: Between this spring's Revolution Medicines success with a KRAS-targeted drug and now Merck and Moderna's success with an mRNA
420.8K views · 4.2K likes
· 469 reposts · 98 replies
Open on X →
@adamfeuerstein Adam, I guess many more people would have signed up if you were more objective vs some of the promising biotech names (and not only critical of their actions). Not only $IBRX, but other good names as well. This is the reason I didn’t sign up, for example.
540 views · 7 likes
· 0 reposts · 1 replies
Open on X →
@adamfeuerstein This Marks guy approved Sarepta's Elevidys for treatment of Duchenne's muscular dystrophy - even though it hit NOWHERE NEAR stat sig on the data. I wonder why. Was he friends with Sarepta's CEO or something?
And NOW, we have a drug, Deramiocel, which hit stat sig
745 views · 22 likes
· 2 reposts · 0 replies
Open on X →
My newsletter is delivered to STAT subscribers inboxes every Thursday morning. Sign up here:
https://t.co/eTSvvKY03i
5.3K views · 11 likes
· 2 reposts · 1 replies
Open on X →
In this week's Biotech Scorecard newsletter: The extremism of the FDA’s Peter Marks and Vinay Prasad has come with costs
Two regulators, two extreme regulatory philosophies, one replacing the other. The rare disease community is suffering whiplash. Drugmakers ( $QURE most
40K views · 123 likes
· 12 reposts · 22 replies
Open on X →
Plus... Deeper cuts from my reporting this week. You asked some very thoughtful questions about the $QURE FDA situation. I responded...
Including: What is "sham surgery" in the context of a Huntington's study? UniQure and the FDA have stridently opposite views. Last night, I
28.5K views · 55 likes
· 3 reposts · 3 replies
Open on X →
@adamfeuerstein You were wrong about $nwbo so why should we sign up for a stock pumper/basher depending on who's paying for his services?
1.8K views · 14 likes
· 3 reposts · 2 replies
Open on X →
@adamfeuerstein Why the hell would I want to sign up a letter from a clown?
614 views · 8 likes
· 1 reposts · 0 replies
Open on X →
Friends - My humble request is that you sign up for the email version of my weekly newsletter. Its contents are also posted on STAT's website, but the email arrives every Thursday at 6:30 am ET which means you can hate-read it over coffee.
https://t.co/eTSvvKY03i
571.3K views · 151 likes
· 11 reposts · 63 replies
Open on X →
Im Vergleich zu Konten gleicher Größe
16 Beiträge aus den letzten 90 Tagen, verglichen mit der Größenklasse 100K–1M Follower. wird weit gezeigt, aber nur wenige dieser Zuschauer reagieren.
Medianaufrufe5 353dieses Konto5 983Median für 100K–1M
Reichweite, %4.08%dieses Konto1.49%Median für 100K–1M
Interaktion, %0.53%dieses Konto0.93%Median für 100K–1M
| Kennzahl | Dieses Konto | Median für 100K–1M | Verhältnis |
|---|---|---|---|
| Medianaufrufe pro Beitrag | 5 353 | 5 983 | 0.89× |
| Reichweite (Aufrufe ÷ Follower) | 4.08% | 1.49% | 2.74× |
| Interaktionsrate | 0.53% | 0.93% | 0.57× |
Weitere Konten dieser Größe → Mit einem anderen Konto vergleichen → Wie diese Vergleichswerte entstehen →
Growth & engagement
How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.
Views per post
5.4K19 Aug
5.3K
2.6K
22.9K2 Sep
32.1K
967
10.2K
756
20.8K
843
47.2K4 Sep
2.5K
1.2K
961
Last 14 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.
Engagement rate per post
0.96%19 Aug
1.40%
2.34%
0.42%2 Sep
0.23%
0.31%
0.57%
0.53%
0.17%
0.36%
0.33%4 Sep
0.53%
0.43%
0.83%
Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.
What the audience does
Likes79.4%19 508 in total
Reposts14.7%3 612 in total
Replies2.2%537 in total
Quotes1.5%362 in total
Bookmarks2.2%552 in total
Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.
The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.
Ähnliche Konten
Ayatollah Mojtaba Khamenei
@MKhamenei_ir
262.6K followers
· 412 posts
jess 🎀 ✓
@jessicahkim
262.6K followers
· 26.1K posts
Bu Tag Neden Var ✓
@taghaberler
262.5K followers
· 23.3K posts
Ministry of Finance, Government of Pakistan ✓
@Financegovpk
262.5K followers
· 10.7K posts
Samsung Türkiye
@SamsungTurkiye
262.5K followers
· 43.5K posts
防衛省・自衛隊（災害対策） ✓
@ModJapan_saigai
262.5K followers
· 3.6K posts
صحيفة المناطق السعودية ✓
@AlMnatiq
262.5K followers
· 548.7K posts
MZZΛ
@MazzaTomas
262.5K followers
· 6.1K posts